Is Ktra a good buy

Kintara Therapeutics (KTRA) does not appear to be a good buy at this time. Here's why:

1. Financial Ratios: KTRA's P/E ratio is negative, indicating that the company is not profitable as the EPS is negative. The P/B ratio is also negative, suggesting that the stock is trading below its book value. A negative P/S ratio further indicates that the market is not valuing the company's sales effectively.

2. Technical Indicators: The stock's 50-day moving average is $0.24, while the 5-day and 10-day moving averages are $0.19 and $0.21, respectively. This indicates a downward trend in the stock price, which is a negative sign.

3. Market Sentiment: There is a bearish sentiment in the market, as evidenced by the stock's 52-week range being between $0.08 and $4.92, with a recent close of $0.19. The stock has also experienced a significant drop, with a 1-year price target of $14.00, which is a long way from the current price.
4. Strategic Developments: Despite strategic collaborations, such as with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China, the company's financials raise concerns.

In conclusion, KTRA's negative financial ratios, downward trending technical indicators, and bearish market sentiment suggest that it is not a good buy at this time.